Terms: = Liver cancer AND EML4, ENSG00000143924, 27436 AND Treatment
17 results:
1. Successful treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene.
Shiraishi T; Yamasaki K; Kidogawa M; Shingu T; Ujimiya F; Jotatsu T; Matsumoto S; Izumi H; Nishida C; Goto K; Yatera K
Intern Med; 2023 Nov; 62(21):3215-3221. PubMed ID: 36927974
[TBL] [Abstract] [Full Text] [Related]
2. Multisystem ALK-positive histiocytosis: a multi-case study and literature review.
Liu W; Liu HJ; Wang WY; Tang Y; Zhao S; Zhang WY; Yan JQ; Liu WP
Orphanet J Rare Dis; 2023 Mar; 18(1):53. PubMed ID: 36915094
[TBL] [Abstract] [Full Text] [Related]
3. Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report.
Zhang Y; Fang H; Hong J; Wang X; Wang H; Pan G
Medicine (Baltimore); 2022 Aug; 101(33):e30094. PubMed ID: 35984185
[TBL] [Abstract] [Full Text] [Related]
4. Special issue "The advance of solid tumor research in China": Real-world clinical outcomes of alectinib for advanced nonsmall-cell lung cancer patients with ALK fusion in China.
Su C; Zhou J; Qiang H; Zhao J; Chang Q; Ji X; Li J; Xie M; Chu T
Int J Cancer; 2023 Jan; 152(1):15-23. PubMed ID: 35579989
[TBL] [Abstract] [Full Text] [Related]
5. Crizotinib: aseptic abscesses in multiple organs during treatment of eml4-ALK-positive NSCLC.
Weber D; Decker M; Schuster M; Folz S; Stürmer CJ; Lutz MP
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3769-3771. PubMed ID: 34373943
[TBL] [Abstract] [Full Text] [Related]
6. Coexistence of a secondary STRN-ALK, eml4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
Zeng Q; Gao H; Zhang L; Qin S; Gu Y; Chen Q
Anticancer Drugs; 2021 Sep; 32(8):890-893. PubMed ID: 34232939
[TBL] [Abstract] [Full Text] [Related]
7. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
[TBL] [Abstract] [Full Text] [Related]
8. Successful Alectinib treatment for Carcinoma of Unknown Primary with
Sugiyama K; Izumika A; Iwakoshi A; Nishibori R; Sato M; Shiraishi K; Hattori H; Nishimura R; Kitagawa C
Curr Oncol; 2021 May; 28(3):1938-1945. PubMed ID: 34064158
[TBL] [Abstract] [Full Text] [Related]
9. Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis-inhibiting pathway.
Yu R; Bai H; Gao B; Li T; He X; Zhang P; Wang J
Thorac Cancer; 2021 Jan; 12(1):128-132. PubMed ID: 33225619
[TBL] [Abstract] [Full Text] [Related]
10. Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and eml4-ALK rearrangement.
Bronte G; Delmonte A; Burgio MA; Verlicchi A; Puccetti M; Bravaccini S; Cravero P; Tumedei MM; Diano D; Rossi G; Ulivi P; Martinelli G; Crinò L
Lung Cancer; 2020 Apr; 142():47-50. PubMed ID: 32088605
[TBL] [Abstract] [Full Text] [Related]
11. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
Takahashi K; Seto Y; Okada K; Uematsu S; Uchibori K; Tsukahara M; Oh-Hara T; Fujita N; Yanagitani N; Nishio M; Okubo K; Katayama R
Thorac Cancer; 2020 Mar; 11(3):581-587. PubMed ID: 31943796
[TBL] [Abstract] [Full Text] [Related]
12. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
[TBL] [Abstract] [Full Text] [Related]
13. Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report.
Madabhavi I; Patel A; Anand A; Panchal H; Parikh S
Clin Respir J; 2018 Feb; 12(2):806-810. PubMed ID: 27606884
[TBL] [Abstract] [Full Text] [Related]
14. Alternate-day treatment with Crizotinib for Drug-induced Esophagitis and liver Damage in a Patient with eml4-ALK Fusion Gene-positive Lung Adenocarcinoma.
Tsukita Y; Fukuhara T; Kobayashi M; Morita M; Suzuki A; Watanabe K; Noguchi T; Kurata Y; Suno M; Maemondo M
Intern Med; 2015; 54(24):3185-8. PubMed ID: 26666609
[TBL] [Abstract] [Full Text] [Related]
15. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.
Castañón E; Rolfo C; Viñal D; López I; Fusco JP; Santisteban M; Martin P; Zubiri L; Echeveste JI; Gil-Bazo I
J Transl Med; 2015 Aug; 13():257. PubMed ID: 26248464
[TBL] [Abstract] [Full Text] [Related]
16. [Atypical metastatic breast localization in lung cancer].
Serraille A; Barazzutti H; Greillier L; Barlesi F
Rev Mal Respir; 2015 Nov; 32(9):953-5. PubMed ID: 26037683
[TBL] [Abstract] [Full Text] [Related]
17. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
[TBL] [Abstract] [Full Text] [Related]